PARP1 and cancer: While the trapping mechanism induced by specific PARP inhibitors might be advantageous for the treatment of certain cancers, this mechanism of action might not be optimal to rescue normal cells from severe oxidative damage during ischemia-reperfusion injury (e.g., ischemia of the lung due to ionizing radiation [136] and cerebral ischemia during surgery [137]).